Aarhus University Seal / Aarhus Universitets segl

Asbjørn Mohr Drewes

The Absorption Profile of Pregabalin in Chronic Pancreatitis

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

The Absorption Profile of Pregabalin in Chronic Pancreatitis. / Olesen, Anne Estrup; Olofsen, Erik; Olesen, Søren Schou; Staahl, Camilla; Andresen, Trine; Dahan, Albert; Drewes, Asbjørn Mohr.

I: Basic & Clinical Pharmacology & Toxicology, Bind 111, Nr. 6, 2012, s. 385-390.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Olesen, AE, Olofsen, E, Olesen, SS, Staahl, C, Andresen, T, Dahan, A & Drewes, AM 2012, 'The Absorption Profile of Pregabalin in Chronic Pancreatitis', Basic & Clinical Pharmacology & Toxicology, bind 111, nr. 6, s. 385-390. https://doi.org/10.1111/j.1742-7843.2012.00914.x

APA

Olesen, A. E., Olofsen, E., Olesen, S. S., Staahl, C., Andresen, T., Dahan, A., & Drewes, A. M. (2012). The Absorption Profile of Pregabalin in Chronic Pancreatitis. Basic & Clinical Pharmacology & Toxicology, 111(6), 385-390. https://doi.org/10.1111/j.1742-7843.2012.00914.x

CBE

Olesen AE, Olofsen E, Olesen SS, Staahl C, Andresen T, Dahan A, Drewes AM. 2012. The Absorption Profile of Pregabalin in Chronic Pancreatitis. Basic & Clinical Pharmacology & Toxicology. 111(6):385-390. https://doi.org/10.1111/j.1742-7843.2012.00914.x

MLA

Olesen, Anne Estrup o.a.. "The Absorption Profile of Pregabalin in Chronic Pancreatitis". Basic & Clinical Pharmacology & Toxicology. 2012, 111(6). 385-390. https://doi.org/10.1111/j.1742-7843.2012.00914.x

Vancouver

Olesen AE, Olofsen E, Olesen SS, Staahl C, Andresen T, Dahan A o.a. The Absorption Profile of Pregabalin in Chronic Pancreatitis. Basic & Clinical Pharmacology & Toxicology. 2012;111(6):385-390. https://doi.org/10.1111/j.1742-7843.2012.00914.x

Author

Olesen, Anne Estrup ; Olofsen, Erik ; Olesen, Søren Schou ; Staahl, Camilla ; Andresen, Trine ; Dahan, Albert ; Drewes, Asbjørn Mohr. / The Absorption Profile of Pregabalin in Chronic Pancreatitis. I: Basic & Clinical Pharmacology & Toxicology. 2012 ; Bind 111, Nr. 6. s. 385-390.

Bibtex

@article{80ea99dc4cf34c57ba59a2f702236e33,
title = "The Absorption Profile of Pregabalin in Chronic Pancreatitis",
abstract = "It was recently shown that pregabalin decreased pain associated with chronic pancreatitis. It is well known that pancreatitis patients suffer from fat malabsorption with accompanying diarrhoea due to loss of exocrine pancreatic enzyme production. This may lead to changes in the mucosal surface in the small intestine and possibly affect the absorption of pregabalin. The pharmacokinetics of pregabalin has never been investigated in patients suffering from chronic pancreatitis. The aim of this study was to develop a population pharmacokinetic model of pregabalin administered to patients with chronic pancreatitis. The pregabalin population pharmacokinetic analysis was conducted on data from fifteen patients with chronic pancreatitis. Each patient received 75 mg of pregabalin (oral capsule). Pregabalin concentrations were measured using a validated liquid chromatographic method. Data analysis was performed using non-linear mixed effects modeling methodology as implemented by NONMEM. A one compartment model with first-order absorption and elimination adequately described pregabalin pharmacokinetics. Time to maximum observed plasma concentration (T(max) ) was 1.53 (95%CI 1.09-2.05). The maximum plasma concentration (C(max) ) was 1.98 μg/ml (95%CI 1.69-2.34) and area under the plasma concentration-time profile (AUC) was 18.2 μg*h/ml (95%CI 14.7-26.3). Pregabalin is well absorbed in patients with chronic pancreatitis and the pharmacokinetic profile of pregabalin is not extensively affected by chronic pancreatitis.",
author = "Olesen, {Anne Estrup} and Erik Olofsen and Olesen, {S{\o}ren Schou} and Camilla Staahl and Trine Andresen and Albert Dahan and Drewes, {Asbj{\o}rn Mohr}",
note = "{\textcopyright} 2012 The Authors Basic & Clinical Pharmacology & Toxicology {\textcopyright} 2012 Nordic Pharmacological Society.",
year = "2012",
doi = "10.1111/j.1742-7843.2012.00914.x",
language = "English",
volume = "111",
pages = "385--390",
journal = "Basic & Clinical Pharmacology & Toxicology",
issn = "1742-7835",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "6",

}

RIS

TY - JOUR

T1 - The Absorption Profile of Pregabalin in Chronic Pancreatitis

AU - Olesen, Anne Estrup

AU - Olofsen, Erik

AU - Olesen, Søren Schou

AU - Staahl, Camilla

AU - Andresen, Trine

AU - Dahan, Albert

AU - Drewes, Asbjørn Mohr

N1 - © 2012 The Authors Basic & Clinical Pharmacology & Toxicology © 2012 Nordic Pharmacological Society.

PY - 2012

Y1 - 2012

N2 - It was recently shown that pregabalin decreased pain associated with chronic pancreatitis. It is well known that pancreatitis patients suffer from fat malabsorption with accompanying diarrhoea due to loss of exocrine pancreatic enzyme production. This may lead to changes in the mucosal surface in the small intestine and possibly affect the absorption of pregabalin. The pharmacokinetics of pregabalin has never been investigated in patients suffering from chronic pancreatitis. The aim of this study was to develop a population pharmacokinetic model of pregabalin administered to patients with chronic pancreatitis. The pregabalin population pharmacokinetic analysis was conducted on data from fifteen patients with chronic pancreatitis. Each patient received 75 mg of pregabalin (oral capsule). Pregabalin concentrations were measured using a validated liquid chromatographic method. Data analysis was performed using non-linear mixed effects modeling methodology as implemented by NONMEM. A one compartment model with first-order absorption and elimination adequately described pregabalin pharmacokinetics. Time to maximum observed plasma concentration (T(max) ) was 1.53 (95%CI 1.09-2.05). The maximum plasma concentration (C(max) ) was 1.98 μg/ml (95%CI 1.69-2.34) and area under the plasma concentration-time profile (AUC) was 18.2 μg*h/ml (95%CI 14.7-26.3). Pregabalin is well absorbed in patients with chronic pancreatitis and the pharmacokinetic profile of pregabalin is not extensively affected by chronic pancreatitis.

AB - It was recently shown that pregabalin decreased pain associated with chronic pancreatitis. It is well known that pancreatitis patients suffer from fat malabsorption with accompanying diarrhoea due to loss of exocrine pancreatic enzyme production. This may lead to changes in the mucosal surface in the small intestine and possibly affect the absorption of pregabalin. The pharmacokinetics of pregabalin has never been investigated in patients suffering from chronic pancreatitis. The aim of this study was to develop a population pharmacokinetic model of pregabalin administered to patients with chronic pancreatitis. The pregabalin population pharmacokinetic analysis was conducted on data from fifteen patients with chronic pancreatitis. Each patient received 75 mg of pregabalin (oral capsule). Pregabalin concentrations were measured using a validated liquid chromatographic method. Data analysis was performed using non-linear mixed effects modeling methodology as implemented by NONMEM. A one compartment model with first-order absorption and elimination adequately described pregabalin pharmacokinetics. Time to maximum observed plasma concentration (T(max) ) was 1.53 (95%CI 1.09-2.05). The maximum plasma concentration (C(max) ) was 1.98 μg/ml (95%CI 1.69-2.34) and area under the plasma concentration-time profile (AUC) was 18.2 μg*h/ml (95%CI 14.7-26.3). Pregabalin is well absorbed in patients with chronic pancreatitis and the pharmacokinetic profile of pregabalin is not extensively affected by chronic pancreatitis.

U2 - 10.1111/j.1742-7843.2012.00914.x

DO - 10.1111/j.1742-7843.2012.00914.x

M3 - Journal article

C2 - 22716224

VL - 111

SP - 385

EP - 390

JO - Basic & Clinical Pharmacology & Toxicology

JF - Basic & Clinical Pharmacology & Toxicology

SN - 1742-7835

IS - 6

ER -